Recent studies have shown that analyses of clinically ascertained families tend to overestimate the risk for monogenic disorders compared with those whose pathogenic variants were identified through incidental findings.9,10 Consequently, determining the frequency, variant spectrum, and rate of clinical medullary thyroid cancer presentation in incidental RET variant carriers, as well as understanding how these differ from clinically ascertained cohorts, is important to informing the current recommendations for incidentally identified cases. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.